Pharsight

Elestrin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7198801 MYLAN SPECIALITY LP Formulations for transdermal or transmucosal application
Jun, 2022

(1 year, 2 months ago)

Elestrin is owned by Mylan Speciality Lp.

Elestrin contains Estradiol.

Elestrin has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Elestrin are:

  • US7198801

Elestrin was authorised for market use on 15 December, 2006.

Elestrin is available in gel, metered;transdermal dosage forms.

The generics of Elestrin are possible to be released after 25 June, 2022.

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 15 December, 2006

Treatment: NA

Dosage: GEL, METERED;TRANSDERMAL

More Information on Dosage

ELESTRIN family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic